期刊文献+

卡维地洛治疗慢性充血性心力衰竭的临床疗效观察 被引量:7

下载PDF
导出
摘要 目的:评价卡维地洛治疗慢性充血性心力衰竭患者的疗效和安全性。方法:充血性心力衰竭患者48例随机分为治疗组(n=26)和对照组(n=22)。两组给予利尿剂、强心剂、血管紧张素转换酶抑制剂,有心绞痛或心肌缺血者应用硝酸酯类药物;治疗组在上述治疗基础上口服卡维地洛,起始剂量3.125mg,2次/d,每2周调整剂量1次,直到最大耐受量(预定目标剂量为50mg/d)。疗程6个月。比较两组治疗前和疗程结束时临床疗效及心功能。结果:治疗组的有效率(88.5%)显著高于对照组(63.6%),差异有显著性(P<0.05)。治疗组左室射血分数、心排血量、左室短轴缩短率、左室舒张末期内径较治疗前明显改善,与对照组比较,差异有显著性(P<0.05)。结论:卡维地洛治疗慢性充血性心力衰竭是安全有效的。
出处 《中国医药导报》 CAS 2008年第11期95-96,共2页 China Medical Herald
  • 相关文献

参考文献3

二级参考文献25

  • 1[11]Santos DJ, Moreno AJ. Inhibition of heart mitochondrial lipid peroxidation by non-toxic concentrations of carvedilol and its analog BM-910228 [J]. Biochem Pharmacol ,2001,61 (2): 155-164.
  • 2[12]Noguchi N, Nishino K,Niki E. Antioxidant action of the antihypertensive drug,carvedilol, against lipid peroxidation [J]. Biochem Pharmacol, 2000, 59 ( 9 ):1069-1076.
  • 3[13]Rossig L, Haendeler J, Mallat Z, et al. Congestive heart failure induces endothelial cell apoptosis :protective role of carvedilol [J]. J Am Coll Cardilo,2001 ,36( 7 ) :2081-2089.
  • 4[14]Romeo F,LiM D,Shi M ,et al. Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells:modulation of Fas/Fsa ligand and caspase-3 pathway [ J ]. Cardiovasc Res, 2000,45 ( 3 ) :788-794.
  • 5[15]Cao F,Chen J,Lopez BL,et al. Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model [ J ]. Eur J Pharmacol,2000,406( 1 ) :109-116.
  • 6[16]Wei S.Chow LT,Sanderson JE,et al. Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction[J]. J Am Coll Cardiol.2000,36( 1 ) :276-281.
  • 7[17]Ohta Y, Watanabe K, Nakazawa M,et al. Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart[ J ]. J Cardiovasc Pharmacol,2000,36 ( suppl 2 ) 19-23.
  • 8[18]Savitz SI, Erhardt JA, Anhtony JV, et al. The novel β-bolcker, carvedilol, provides neuroprotection in transient focal stroke[J]. J Cereb Blood Flow Metab,2000,20(8) :1197-1204.
  • 9[19]Karle CA, Kreye VA,Thomas D, et al. Antarrhythmic drug carvedilol inhibits HERG potassium channels [ J ]. Cardiovasc Res,2001,49 ( 2 ): 361-370.
  • 10[20]Takusagawa M, Komori S, Matsumura K, et al. The inhibitory effects of carvedilol against arhytmias induced by coronary by coronary reperfusion in aneothetized rats [J]. J Cardiovasc Pharmacol Ther, 2000, 5 ( 2 ): 105 - 112.

共引文献2501

同被引文献25

  • 1吴学思.慢性心力衰竭的诊断和治疗进展[J].中国实用内科杂志:临床前沿版,2006,26(3):408-410. 被引量:38
  • 2王知军,张立功.充血性心力衰竭的现代研究新进展[J].中国心血管病研究,2006,4(9):708-710. 被引量:19
  • 3Packer M. Effect of carvedilol on the survival of patients with chronic heart failure[J]. Circulation,1995,92(1) : 126-142.
  • 4Ogawa Y,Nakao K,Mukoyama M,et al.Natriuretic peptides as cardiac hormones in normal and spontaneously hypertensive rats.The ventricle is a mayor site of synthesis and secretion of brain natriuretic peptide[J]. Circ Res, 1991,69(2) :431-500.
  • 5Clerio A, Lervasi G, Chicca M, et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP)measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure [J].J Endocrinolluvest, 1998,21:170- 179.
  • 6Alan Maisel. b-Type Natriuretic Peptide Level:Diagonostic and Prognostic in Congestive Heart Failure[J]. Circulation, 2002,105:2328.
  • 7Michalsen A,Konig G,Thimme W,et al.Preventable causative factors leading to hospital admission with decompensated heart failure (see comments)[J].Heart,2008,80(5):437-441.
  • 8Bristow,M.R. Adrenergic receptor biockade in chronic heart failure[J].Circulation,2009,(05):558-569.
  • 9Bristow,M.R. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure[J].Circulation,2006,(11):2807-2816.
  • 10Krum H. Effects of initiating carvedilol in patients with severe chronic heart failure[J].Journal of the American Medical Association,2003,(06):712-718.

引证文献7

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部